-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Jazz Pharmaceuticals (JAZZ)
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $275 at Stifel
-
-
-
-
-
-
-
Canaccord Starts Jazz Pharmaceuticals (JAZZ) at Buy
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $301 at Piper Sandler
-
-
-
-
-
-
-
Jazz Pharmaceuticals (JAZZ) PT Raised to $232 at Piper Sandler
-
-
-
-
-
-
-
Boehringer Ingelheim partners with Jazz Pharmaceuticals on breast cancer study
-
-
-
-
-
-
-
RBC on Jazz (JAZZ): 'Downside Move on HERIZON-GEA Data Leak Unwarranted - Zani Regimens Are Clearly Active and Will See Use'
-
483,151 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


